The State Street Health Care Select Sector SPDR ETF (XLV) seeks to match the Health Care Select Sector Index, which is essentially the S&P 500’s health care constituents (pharma, biotech, equipment, providers, and managed care) weighted by market cap. That means performance is dominated by a handful of mega-caps—especially Eli Lilly, Johnson & Johnson, AbbVie, and UnitedHealth—so even modest moves in those names can translate into a small index-level decline.

The most actionable health-care-specific macro driver in the tape has been Medicare Advantage payment and rules clarity. CMS finalized a higher-than-feared 2027 Medicare Advantage rate increase (about 2.48%), which helped sentiment in the managed-care complex, but investors are still focused on whether medical cost trends (utilization) will absorb the rate benefit and whether rating/quality-rule changes shift profitability across plans. Because XLV has meaningful exposure to managed care via UnitedHealth and peers, lingering uncertainty around insurer margins can keep a lid on the whole ETF even when pharma and medtech are steadier.

Even though health care is often treated as defensive, the sector can still slip when long-dated yields are elevated because investors demand more earnings yield from equities (a higher discount rate). Recent rate prints show the 10-year Treasury staying in the mid-4% area, which tends to pressure valuation-heavy leaders (including large pharma/biotech) and can lead to small, broad-based ETF weakness without a single stock-specific headline.

A 0.40% down day is consistent with a mixed-to-soft session in the largest constituents rather than an ETF-specific shock. If the decline persists, the next things investors usually watch for XLV are: (1) insurer updates around Medicare Advantage pricing and medical-loss ratios, (2) any large-cap pharma headline risk (drug pricing, litigation, trial readouts), and (3) whether bond yields re-accelerate upward, which can extend multiple compression across mega-cap healthcare.